-

Proteintech Group Enters Cellular Multiomics Market with New Subsidiary Genomics Company

SAN DIEGO--(BUSINESS WIRE)--Proteintech Group today announces that it has established a new subsidiary company, Proteintech Genomics, based out of the thriving life sciences hub of San Diego, California. Proteintech Genomics is building out fully optimized and highly multiplexed proteomic assays to enhance multiomic capabilities across a number of spatial and single cell analysis platforms. The company plans to establish partnerships with leading single cell and spatial analysis companies to develop proteomic assays that can be used together with existing RNA or DNA profiling products.

“Our goal is to unleash the power of multiomics broadly throughout the research community,” said Dr. Kristopher Nazor, CEO, Proteintech Genomics. “This can only be achieved via commercialization of powerful proteomic assays that are highly multiplexed, fully optimized, simple to use, and above all else, reliable.”

“Working as part of the Proteintech Group family of companies provides us with unfettered access to two critical resources,” said Nazor, “An industry-best portfolio of highly validated antibodies targeting the vast majority of the annotated human proteome, and the immense scientific expertise of the teams responsible for building out this industry-best catalog of 15,000+ antibodies.”

“We are excited to announce this new subsidiary within the Proteintech Group family,” said Dr. Jason Li, CEO, Proteintech Group. “The team at Proteintech Genomics has demonstrated leadership in the field of single cell multiomics and there is no limit to what we can achieve together,” adding, “We expect to make a swift and significant impact in the fields of single cell and spatial analysis.”

About Proteintech Genomics

Proteintech Genomics is life science technology company empowering the research community with the discovery potential of single cell and spatial multiomics. The company is developing fully optimized and highly multiplexed proteomic assays that can be readily integrated into various single cell and spatial analysis application workflows. Proteintech Genomics was founded as a subsidiary of the Proteintech Group in 2022 and opened its state-of-the-art San Diego facility in July 2022.

About Proteintech Group

Proteintech is a life sciences reagent company that manufactures and sells antibody, nanobody, and protein products to support the applications of proteomics, cell culture, and cGMP biomanufacturing for its customers in academia and pharma. To maintain the highest level of quality control, the company exclusively sells its own products, manufactured in house, leading to superior reproducibility and lot-to-lot consistency. With over 2/3 target coverage of proteins encoded by the human genome, Proteintech’s 13,000+ antibodies are used every day by scientists all over the world in a wide spectrum of research areas. To view tens of thousands of publications and in-house validation images in WB, IHC, IF, FC, IP, and CHIP using its antibodies and to learn more about Proteintech and their mission to deliver products directly from their bench to the researcher’s bench, please visit www.ptglab.com.

Contacts

Katie Bellows
katie@ptglab.com

More News From Proteintech Group

Proteintech Launches “Able” AI – A First-of-Its-Kind Tool to Accelerate Scientific Discovery

ROSEMONT, Ill.--(BUSINESS WIRE)--Proteintech, a global leader in antibodies and life science solutions, today announced the launch of Able AI, a first-of-its-kind artificial intelligence tool that is now available on ptglab.com. Finding the most suitable antibodies from the vast pool of potential products is a challenge. Able helps scientists pinpoint the right antibody based on their research needs, while also providing all relevant information and associated scientific knowledge. In addition,...

Proteintech Unveils Next-Gen 3D Epitope Mapping to Accelerate Life Science Research

ROSEMONT, Ill.--(BUSINESS WIRE)--Proteintech, a global leader in antibodies and life science solutions, is excited to announce additional product characterization for primary antibody targets on its website (ptglab.com). The advanced validation data, 3D Epitope Mapping, is designed to enhance the efficiency and accuracy of antibody-related selection, empowering scientists with the data they need to advance their work, from basic research to the design of novel therapeutics. The 3D Epitope Mappi...

Proteintech Genomics Launches the MultiPro® Human Discovery Panel: A New Frontier in Single-Cell Multiomics

SAN DIEGO--(BUSINESS WIRE)--Proteintech Genomics, a leader in antibody-based multiplexed solutions for single-cell multiomics, today announced the launch of its MultiPro® Human Discovery Panel, a groundbreaking antibody panel designed to transform single-cell multiomics research. This new panel enables scientists to profile 325 proteins alongside whole transcriptome analysis within single cells, offering a multiomic approach that delivers deeper insights into cellular functions. The MultiPro® H...
Back to Newsroom